Beta Bionics, Inc. (BBNX) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "BBNX"
      ],
      "issuer_cik": "0001674632",
      "owner_cik": "0002048497",
      "accession_number": "0002048497-26-000021",
      "form_type": "4",
      "filing_date": "2026-10-16",
      "period_of_report": "2026-10-14",
      "issuer_name": "Beta Bionics, Inc.",
      "issuer_trading_symbol": "BBNX",
      "owner_name": "Hopman Mark",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "Chief Commercial Officer",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": false,
      "transaction_date": "2026-10-14",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 775,
      "transaction_price_per_share": 17.35,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 55334,
      "transaction_value": 13446.250000000002,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026."
        },
        {
          "id": "F2",
          "description": "The weighted average sale price for the transaction reported was $17.35 and the range of prices were between $17.35 and $18.3499. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."
        }
      ]
    },
    {
      "tickers": [
        "BBNX"
      ],
      "issuer_cik": "0001674632",
      "owner_cik": "0002048497",
      "accession_number": "0002048497-26-000018",
      "form_type": "4",
      "filing_date": "2026-10-05",
      "period_of_report": "2026-10-01",
      "issuer_name": "Beta Bionics, Inc.",
      "issuer_trading_symbol": "BBNX",
      "owner_name": "Hopman Mark",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "Chief Commercial Officer",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": false,
      "transaction_date": "2026-10-01",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 370,
      "transaction_price_per_share": 18.96,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 56109,
      "transaction_value": 7015.200000000001,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026."
        },
        {
          "id": "F2",
          "description": "The weighted average sale price for the transaction reported was $18.96 and the range of prices were between $18.96 and $19.9599. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."
        }
      ]
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.